Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) reported launch of two new dental products. OroGenix Oral Hygiene Rinse is Sonoma’s second dental product in the United States and developed with its partner in Gabriel Science, LLC. In Switzerland, Sonoma and partner, Medical Systems Solutions has launched Microdacyn Oral Care for professional and consumer use. After its recent successful launch of Endocyn for root canal irrigation in December 2020, Sonoma’s second dental product within the United States is an oral hygiene rinse. OroGenix Oral Hygiene Rinse utilizes Sonoma’s patented Microcyn technology to cleanse gums, teeth and mouth. “We believe the OroGenix Oral Hygiene Rinse and the Microcyn family of hypochlorous acid products will help dentists and their patients achieve healthy gums, teeth, and oral cavity,” said Dr. Mark Fontenot, managing member at Gabriel Science, LLC.
“Microdacyn60® Oral Care offers a superior alternative for oral and throat care. Not only in dentistry, but also in general oral and pharyngeal care such as intubated patients, we see the great benefits of Microdacyn60 Oral Care as an alternative for widely used chlorhexidine-based products,” commented Mr. Edgar Sommer, General Manager at Medical System Solutions.
“We are pleased to bring the oral rinse to dental offices in the U.S., and for both professional and consumer use in Europe. Gabriel Science and Medical System Solutions are ideal partners for advancing our dental and oral care line of products,” said Bruce Thornton, COO of Sonoma Pharmaceuticals. “Our proprietary Microcyn technology is truly the next-generation formulation in terms of superior antimicrobial impact, shelf stability and safety.”